Lineage Cell Therapeutics, Inc. Overview
Pro stress-test →Lineage is a clinical-stage biotechnology company developing novel allogeneic, or "off-the-shelf," cell therapies for serious neurological and ophthalmic conditions. Functional cells developed from such lineages that are relevant to the underlying condition are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or enhance the patient's functional activity.
Strategic Profile
Pro stress-test →The company's business strategy is to efficiently leverage its technology platform and its development and manufacturing capabilities to advance its programs internally or in conjunction with strategic partners to further enhance their value and probability of success. OpRegen's uniquely durable treatment effects last up to 24 months, with a 36-month data update from Roche and Genentech forthcoming. The company received a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits from Factor Bioscience Inc., marking a successful milestone in their strategic collaboration.
Competitive Landscape
Pro stress-test →Lineage specializes in developing regenerative cell-based therapies, focusing on regenerating or replacing damaged tissues using pluripotent cell technology, offering broader therapeutic potential compared to traditional drugs aimed at molecular targets. The company competes in the cell therapy and regenerative medicine space with other developers of allogeneic cell therapies, autologous therapies, and traditional pharmaceutical approaches for similar indications.
Industry Context
Lineage Cell Therapeutics, Inc. operates in Biotechnology - Cell Therapy & Regenerative Medicine.
Key facts
Founded: 1990 · Headquarters: Carlsbad, California · Revenue: $9.5M (2024) · Market cap: $225M